Steven Cohen Ligand Pharmaceuticals Inc Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$65.67 - $77.08 $5,319 - $6,243	81 New	81 $5,000
Q2 2022 Aug 15, 2022	SELL	$74.52 - $117.06 $6.16 Million - $9.67 Million	-82,600 Reduced 96.61%	2,900 $259,000
Q1 2022 May 16, 2022	BUY	$94.99 - $151.56 $2.98 Million - $4.76 Million	31,400 Added 58.04%	85,500 $9.62 Million
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $6.91 Million - $8.97 Million	54,100 New	54,100 $8.36 Million
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $182,767 - $240,627	-2,269 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $203,211 - $287,527	2,269 New	2,269 $216,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.97B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.